GSK granted option on pneumococcal vaccine proteins
This article was originally published in Scrip
Executive Summary
The Israeli start-up Protea Vaccine Technologies has entered a collaboration and option agreement that grants GlaxoSmithKline Biologicals the option to obtain an exclusive licence to a set of Protea’s conserved pneumococcal proteins for the development and commercialisation of a universal protein-based Streptococcus pneumoniae vaccine. Protea is affiliated with another Israeli vaccine firm NasVax.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.